+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C - Pipeline Review, H1 2020

  • ID: 5017455
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 414 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Pharma Ltd
  • Biotron Ltd
  • F. Hoffmann-La Roche Ltd
  • HEC Pharm Co Ltd
  • MetalloPharm LLC
  • Riboscience LLC
  • MORE
Hepatitis C - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 9, 15, 3, 35, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 13 and 17 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Pharma Ltd
  • Biotron Ltd
  • F. Hoffmann-La Roche Ltd
  • HEC Pharm Co Ltd
  • MetalloPharm LLC
  • Riboscience LLC
  • MORE
  • Introduction
  • Hepatitis C - Overview
  • Hepatitis C - Therapeutics Development
  • Hepatitis C - Therapeutics Assessment
  • Hepatitis C - Companies Involved in Therapeutics Development
  • Hepatitis C - Drug Profiles
  • Hepatitis C - Dormant Projects
  • Hepatitis C - Discontinued Products
  • Hepatitis C - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Hepatitis C, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hepatitis C - Pipeline by AB Pharma Ltd, H1 2020
  • Hepatitis C - Pipeline by AbbVie Inc, H1 2020
  • Hepatitis C - Pipeline by AIMM Therapeutics BV, H1 2020
  • Hepatitis C - Pipeline by Akshaya Bio Inc, H1 2020
  • Hepatitis C - Pipeline by Alla Chem LLC, H1 2020
  • Hepatitis C - Pipeline by Ascletis Pharma Inc, H1 2020
  • Hepatitis C - Pipeline by Atea Pharmaceuticals Inc, H1 2020
  • Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2020
  • Hepatitis C - Pipeline by Beta Pharma Inc, H1 2020
  • Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H1 2020
  • Hepatitis C - Pipeline by Biotron Ltd, H1 2020
  • Hepatitis C - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Hepatitis C - Pipeline by Bolder Biotechnology Inc, H1 2020
  • Hepatitis C - Dormant Projects, H1 2020
  • Hepatitis C - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Hepatitis C, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AB Pharma Ltd
  • AbbVie Inc
  • AIMM Therapeutics BV
  • Akshaya Bio Inc
  • Alla Chem LLC
  • Ascletis Pharma Inc
  • Atea Pharmaceuticals Inc
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Beta Pharma Inc
  • Biotest Pharmaceuticals Corp
  • Biotron Ltd
  • Boehringer Ingelheim International GmbH
  • Bolder Biotechnology Inc
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Cocrystal Pharma Inc
  • Combioxin SA
  • DEKK-TEC Inc
  • Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
  • Ena Therapeutics Pty Ltd
  • Ennaid Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • FortuneRock (China) Ltd
  • Galactica Biotech Ltd
  • GeneCure LLC
  • Genoscience Pharma
  • Gilead Sciences Inc
  • GinkgoPharma Co Ltd
  • GlaxoSmithKline Plc
  • HEC Pharm Co Ltd
  • Hepion Pharmaceuticals Inc
  • ImmuneMed Inc
  • ImmunoBiology Ltd
  • Immunotope Inc
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • iQur Ltd
  • J2H Biotech
  • Medivir AB
  • Merck & Co Inc
  • MetalloPharm LLC
  • Microbio Co Ltd
  • MultiCell Technologies Inc
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • Nanogen Biopharmaceutical Co
  • Novalex Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Palisades Therapeutics
  • PharmaEssentia Corp
  • Presidio Pharmaceuticals Inc
  • Profectus BioSciences Inc
  • Regulus Therapeutics Inc
  • Riboscience LLC
  • Rodos BioTarget GmbH
  • Savoy Pharmaceuticals Inc
  • Shanghai Newsummit Biopharma Co Ltd
  • Shanghai Tangrun Pharmaceuticals Co Ltd
  • Sino Biopharmaceutical Ltd
  • Sudershan Biotech Ltd
  • TaiGen Biotechnology Co Ltd
  • Tetranov International Inc
  • TGV Laboratories Inc
  • Therapure Biopharma Inc
  • THEVAX Genetics Vaccine USA Inc
  • Toray Industries Inc
  • Trek Therapeutics PBC
  • UBI Pharma Inc
  • Vanworld Pharmaceutical (Rugao) Company Ltd
  • Vertex Pharmaceuticals Inc
  • Virocovax
  • Zylacta Corp
Note: Product cover images may vary from those shown
Adroll
adroll